2. Academic Validation
  3. Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure

Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure

  • J Biomed Sci. 2025 Jul 6;32(1):61. doi: 10.1186/s12929-025-01162-6.
Yasufumi Katanasaka 1 2 3,  Yoichi Sunagawa 4 5 6,  Ryoga Sakurai 4,  Mikuto Tojima 4,  Ryuya Naruta 4,  Yuya Hojo 4,  Yuto Kawase 4,  Toshihide Hamabe-Horiike 4,  Kiyoshi Mori 6 7 8,  Koji Hasegawa 5,  Tatsuya Morimoto 9 10 11
Affiliations

Affiliations

  • 1 Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan. katana@u-shizuoka-ken.ac.jp.
  • 2 Division of Translational Research, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan. katana@u-shizuoka-ken.ac.jp.
  • 3 Shizuoka General Hospital, 4-27-1 Kita Ando Aoi-ku, Shizuoka, 420-8527, Japan. katana@u-shizuoka-ken.ac.jp.
  • 4 Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
  • 5 Division of Translational Research, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan.
  • 6 Shizuoka General Hospital, 4-27-1 Kita Ando Aoi-ku, Shizuoka, 420-8527, Japan.
  • 7 Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, 4200881, Japan.
  • 8 Department of Molecular and Clinical Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, 4228526, Japan.
  • 9 Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan. morimoto@u-shizuoka-ken.ac.jp.
  • 10 Division of Translational Research, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho Fukakusa, Fushimi-ku, Kyoto, 612-8555, Japan. morimoto@u-shizuoka-ken.ac.jp.
  • 11 Shizuoka General Hospital, 4-27-1 Kita Ando Aoi-ku, Shizuoka, 420-8527, Japan. morimoto@u-shizuoka-ken.ac.jp.
PMID: 40619438 DOI: 10.1186/s12929-025-01162-6
Abstract

Background: Various epigenetic modifiers are involved in the regulation of gene expression during pathological cardiac hypertrophy-a critical event in the development of heart failure. Our previous research has demonstrated that protein arginine methyltransferase 5 (PRMT5) in cardiac fibroblasts is a crucial epigenetic writer implicated in pathological cardiac fibrosis. Moreover, treatment with a PRMT5 Inhibitor also suppressed cardiac hypertrophy in mice after transverse aortic constriction (TAC) surgery. However, as the functional role of PRMT5 in cardiomyocytes remains to be fully elucidated in pathological cardiac hypertrophy and systolic dysfunction, this study aimed to clarify the gain-of-function of PRMT5 in cardiomyocytes.

Methods: Cardiac-specific PRMT5 transgenic (PRMT5-TG) mice were generated to evaluate the gain-of-function of PRMT5 in cardiac hypertrophy and dysfunction in male mice undergoing TAC surgery. Cardiac function and myocardial cell hypertrophy were evaluated in wild-type (WT) and PRMT5-TG mice after TAC surgery. To elucidate the molecular mechanistic basis through which PRMT5 induces cardiomyocyte hypertrophy, we examined epigenetic modifications of histones in cardiomyocytes.

Results: Echocardiography revealed that fractional shortening was reduced in PRMT5-TG mice compared to WT mice after TAC surgery. Both heart weight/BW and lung weight/BW ratios increased significantly more in PRMT5-TG than in WT mice. Histological analyses showed that cardiomyocyte diameter and perivascular fibrosis were elevated in PRMT5-TG mice in comparison to WT mice. Hypertrophic gene expression significantly increased in PRMT5-TG mice after TAC surgery. In primary cultured neonatal rat cardiac myocytes, EPZ015666, a specific inhibitor of PRMT5, and PRMT5 knockdown significantly inhibited phenylephrine (PE)-induced cell hypertrophy. Cardiac overexpression of PRMT5 promoted the acetylation of H3K9, a histone marker associated with cardiomyocyte hypertrophy, and the Histone Acetyltransferase activity of p300. Conversely, treatment with EPZ015666 reduced the acetylation of H3K9 induced by TAC surgery and PE treatment. Finally, we found that PRMT5 interacts with and methylates p300 at R200. The R200 point mutation in p300 abolished PRMT5-mediated enhancement of its Histone Acetyltransferase activity.

Conclusions: The gain-of-function of PRMT5 in cardiomyocytes exacerbates pressure overload-induced cardiac hypertrophy and left ventricular systolic dysfunction, at least partially, through p300 methylation and Histone Acetyltransferase activation.

Keywords

Arginine methylation; Cardiac hypertrophy; Heart failure; Histone acetyltransferase; Protein arginine methyltransferase 5; p300.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z